Please login to the form below

sarcoma

This page shows the latest sarcoma news and features for those working in and with pharma, biotech and healthcare.

Nektar’s opioid analgesic slammed with FDA panel rejection

This includes studies, either underway or planned, in small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer, sarcoma, melanoma, renal cell carcinoma, bladder cancer and

Latest news

MD Anderson exec Stephen Hahn to be nominated FDA commissioner

He is also specialist in lung cancer and sarcoma, and climbed up the centre’s professional ladder since joining in 2015.
Bicycle Therapeutics looks to raise $86m with IPO

breast, lung, sarcoma, gastric, bladder, endometrial, ovarian and oesophageal cancers.
CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed
Lilly to withdraw Lartruvo, a first for accelerated approval failures

Existing patients can use access programme. Eli Lilly is to withdraw its soft tissue sarcoma treatment Lartruvo from the market after it failed a post-marketing efficacy study. ... Advanced soft tissue sarcoma is a rare and difficult-to-treat cancer.
Positive data unlocks more EIB funding for Nanobiotix

as well as an independent assessment of the clinical benefit/risk ratio for NBTXR3 in a phase 3 programme in soft tissue sarcoma (STS).

More from news
Approximately 5 fully matching, plus 47 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),
Case study: Treatment guidance

The Practical Guide was launched as part of a Takeda sponsored symposium at the British Sarcoma Group’s annual conference.
Pharma deals during February 2014

Also, this month Merck &Co has handed back the rights to Ariad Pharmaceutical's ridaforolimus, a mTOR inhibitor in a phase III trial for advanced sarcoma.
Interview: Harvey Berger and Timothy Clackson, Ariad

And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the front-runner in the company's pipeline

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

5 creative tactics for your patient recruitment strategies

Videos such as this one from the Sarcoma UK Clinical Trials Hub explain how trials work, answer typical questions and present the benefits to possible participants.
World AIDS Day 2018: Fighting the stigma surrounding HIV

2. Characterised by very low levels of CD4+ T cells, and the presence of AIDS-related pathologies (such as tuberculosis and Kaposi’s sarcoma), the diagnosis of AIDS marks just how

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Group Account Director, Patient Engagement & Solutions, Lond...: Highly competitive salary

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Account Director, Publications, Women’s health, Medical C...: Highly competitive salary

Senior Medical Writer, Rare diseases, Medical Communications age...: Highly competitive salary

Senior Account Manager: Salary TBC

FREELANCE (Outside IR35) Opportunities for this week below!!!: Superb Day Rate

Publications Director: Competitive Salary

Client Services Director, Patient Engagement & Solutions, Lo...: Highly competitive salary

Medical Writer, Women’s health, Medical Communications agency, h...: Highly competitive salary

Planner: Salary TBC

Senior Account Director, Publications, Opthalmology, Medical Com...: Highly competitive salary

Account Director, Publications, Opthalmology, Medical Communicat...: Highly competitive salary

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

PMHub

Add my company

SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed: By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
How early-stage clinical research is facilitating the new wave of personalised medicines: By Jorg Taubel...
Patient diversity in clinical trials needs to be centre stage: By Danny Buckland...

Email:
Password:

Please login to the form below

sarcoma

COVID-19 Updates and Daily News

Featured jobs

Quick links